Please assess the completion status of the following clinical trial:

Trial Title: Elucidation of Acid-Induced Pulmonary Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. chronic cough consistent with bronchoreactivity~2. Gastroesophageal reflux~Exclusion Criteria:~1. Severe asthmatics who have been hospitalized within the last 6 months or who have required oral steroid use within the last 4 weeks~2. Severe coronary artery disease~3. Cigarette/cigar smoking within the last 6 months~4. Documented allergies affecting the respiratory system~5. Subjects with contraindications to pH/impedance probe~   1. Hemophilia~  2. Septal deviation~6. Subjects with contraindications to bronchoscopy as outlined by the American Thoracic Society Guidelines~7. Anticoagulation~8. Pregnancy~9. Incarcerated patients~10. Current oral steroid use (may suppress levels of inflammation)~11. Upper respiratory infection within the last 2 weeks~12. Ongoing acid suppression with a proton pump inhibitor, however, patients may be included if they have discontinued their proton pump inhibitor within the last 1 month with stable asthma symptoms as defined by stable utilization of inhaled steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lansoprazole therapy (Type: ACTIVE_COMPARATOR): Lansoprazole 30 mg orally twice daily
- Placebo (Type: PLACEBO_COMPARATOR): placebo orally twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).